[Form 4] The Cigna Group Insider Trading Activity

Filing Impact

(High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

Nicole S. Jones, EVP, Chief Administrative Officer and General Counsel of The Cigna Group (CI), reported multiple transactions under a Rule 10b5-1 plan. On 08/15/2025 and 08/18/2025 she executed option exercises and open-market trades: option-related acquisitions of 13,155 and 11,598 shares at exercise prices of $197.35 and $183.4405, additional option exercises of 1,348 and 1,329 shares, and a reported sale of 28,526 shares at $300 on 08/15/2025. Following these transactions her reported beneficial ownership positions changed across reported lines (examples shown: 42,576; 54,174; 25,648; 26,996; 28,325). She also holds 1,419.6518 shares indirectly via the company 401(k) plan. The Form 4 states the trades were effected pursuant to a 10b5-1 plan adopted May 8, 2025, and lists Tyler Gratton as attorney-in-fact who signed the filing on 08/19/2025.

Insights

TL;DR: Insider executed option exercises and a sizeable sale under a pre-established 10b5-1 plan; transactions are material to insider holdings.

The reported Form 4 shows simultaneous option exercises and an open-market sale on 08/15/2025 with follow-up option-related purchases on 08/18/2025. The sale of 28,526 shares at $300 is the largest single disposition disclosed and meaningfully alters reported direct holdings on the form. The filing explicitly identifies the trades as pursuant to a Rule 10b5-1 plan adopted 05/08/2025, which documents pre-arranged timing and may limit contemporaneous trading interpretation. All figures and dates are taken directly from the filing.

TL;DR: Transactions were executed under a 10b5-1 plan and include option exercises and 401(k) participation; procedural disclosures appear complete.

The Form 4 discloses option exercises at stated exercise prices ($183.4405 and $197.35), purchases reported as resulting from those exercises, and indirect ownership via the 401(k). The filing includes the 10b5-1 adoption date and an attorney-in-fact signature, consistent with standard insider reporting practices. The report lists Jones's corporate title and relationship to the issuer, meeting disclosure requirements shown in the document.

08/19/2025 - 05:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Nicole S

(Last)

(First)

(Middle)

900 COTTAGE GROVE ROAD

(Street)

BLOOMFIELD

06002

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Cigna Group [ CI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, $.01 Par Value	08/15/2025		M⁽¹⁾		13,155	A	$197.35	42,576	D
Common Stock, $.01 Par Value	08/15/2025		M⁽¹⁾		11,598	A	$183.4405	54,174	D
Common Stock, $.01 Par Value	08/15/2025		S⁽¹⁾		28,526	D	$300	25,648	D
Common Stock, $.01 Par Value	08/18/2025		M⁽¹⁾		1,348	A	$183.4405	26,996	D
Common Stock, $.01 Par Value	08/18/2025		M⁽¹⁾		1,329	A	$197.35	28,325	D
Common Stock, $.01 Par Value								1,419.6518⁽²⁾	I	By 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (Right to Buy)	$183.4405	08/15/2025		M⁽¹⁾			11,598	02/27/2020⁽³⁾	02/27/2029	Common Stock, $.01 Par Value	11,598	$0.0000	1,348	D
Employee Stock Option (Right to Buy)	$197.35	08/15/2025		M⁽¹⁾			13,155	02/28/2019⁽⁴⁾	02/28/2028	Common Stock, $.01 Par Value	13,155	$0.0000	1,329	D
Employee Stock Option (Right to Buy)	$183.4405	08/18/2025		M⁽¹⁾			1,348	02/27/2020⁽³⁾	02/27/2029	Common Stock, $.01 Par Value	1,348	$0.0000	0.0000	D
Employee Stock Option (Right to Buy)	$197.35	08/18/2025		M⁽¹⁾			1,329	02/28/2019⁽⁴⁾	02/28/2028	Common Stock, $.01 Par Value	1,329	$0.0000	0.0000	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025.

2. Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.

3. This option was granted on February 27, 2019. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date.

4. This option was granted on February 28, 2018. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date.

Remarks:

EVP, Chief Administrative Officer and General Counsel

	Tyler Gratton, attorney-in-fact	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

AG真人官方